E2F-1 induces p53 accumulation and E2F-1 and p53 form a physical complex, which aects the ability of E2F-1 to activate transcription. We mapped the domains on E2F-1 that interact with p53 and found two p53-binding domains. To understand the functional consequences of the E2F-1/p53 association on p53 activities we identi®ed the domains of E2F-1 that were responsible for the accumulation of p53. Unexpectedly, we found that the E2F-1 transactivation domain was dispensable for p53 induction. By contrast, further deletion of the DP-1 interaction/`marked' box domain eliminated p53 accumulation. Radiolabeling pulse/chase analysis demonstrated that E2F-1 caused post-translational stabilization of p53. Although E2F-1 caused the stabilization of p53, E2F-1 expression impaired p53-dependent transactivation. Thus, the E2F-1 : p53 interaction may provide a checkpoint function to inactivate overactive E2F-1, but the association may also inactivate p53 transactivation to allow cell cycle progression. Oncogene (2001) 20, 910 ± 920.
Introduction
The E2F-1 transcription factor is a key regulator of cell cycle progression (Adams and Kaelin, 1995; Dobrowolski et al., 1994; Johnson et al., 1993; Shan and Lee, 1994) . E2F-1 is the most characterized member of a family of six related transcription factors, and coordinately activates genes necessary for the G 1 to S phase transition including DNA polymerase a, dihydrofolate reductase, thymidine kinase, thymidylate synthase, cyclins (D1, A, E), and E2F-1 itself (Almasan et al., 1995; Blake and Azizkhan, 1989; Dou et al., 1992; Hiebert et al., 1991; Ohtani et al., 1995; Pearson et al., 1991; Sala et al., 1994; Schulze et al., 1995) . In cells, E2F-1 forms heterodimers with DP-1, which markedly potentiates E2F DNA binding and transactivation functions (Bandara et al., 1993; Helin et al., 1993; Krek et al., 1993; La Thangue, 1994) .
E2F' is a central eector of the retinoblastoma (pRb) tumor suppressor pathway. When bound to hypophosphorylated forms of pRb (Chellappan et al., 1991) , or to the pRb family members p107 or p130, E2F is prevented from activating transcription and/or these complexes actively repress transcription (Brehm et al., 1998; Hiebert et al., 1992; Magnaghi-Jaulin et al., 1998; Weintraub et al., 1992) . Following mitogen stimulation, pRb becomes phosphorylated by cyclin/ cyclin-dependent kinase (cdk) complexes, resulting in the release of free E2F-1 (Bremner et al., 1995; Dynlacht et al., 1994; Kato et al., 1993) , which stimulates its targets and cell cycle progression. Therefore, the activity of E2F-1 can also be indirectly modulated by cdk inhibitors, including p15 ink4b , p16 ink4a , p21 cip1/waf1 , and p27 Kip1 (Hannon and Beach, 1994; Hunter and Pines, 1994; Serrano et al., 1993; Sherr and Roberts, 1995) , which prevent cyclin/cdk phosphorylation of pRb. Inactivation of these tumor suppressors by mutation, or by the interaction of pRb with DNA tumor virus oncoproteins such as adenovirus E1A, leads to the activation of E2F. In fact, the pRb pathway appears to be one of the most frequently mutated targets in human cancer (Weinberg, 1991) .
In tumors having mutations in the pRb pathway, the tumor suppressor p53 is also usually inactivated (Schener et al., 1991) , and DNA tumor viruses inactivate both pRb and p53 to induce transformation. Thus, one of the ®rst lines of defense in response to the disruption of the pRb pathway appears to be p53. Expression of E1A or E2F-1 leads to the induction of p53 (Debbas and White, 1993; Hiebert et al., 1995; Nip et al., 1997) , and in some cell types, E1A-and E2F-1-induced apoptosis is p53-dependent, or is enhanced by overexpression of p53 Qin et al., 1994; Wu and Levine, 1994) . Thus, E2F-1 appears to link the p53 and pRb tumor suppressor pathways. In support of this concept, the p19 ARF gene, which induces the stabilization of p53 Pomerantz et al., 1998; Zhang et al., 1998) is activated by E2F-1 in primary ®broblasts .
The p53 tumor suppressor functions as an essential component of the DNA damage response that reduces the probability of cells acquiring oncogenic mutations (Lane, 1992) . p53 mediates G 1 arrest or apoptosis of cells following DNA damage (Finlay et al., 1989; Kuerbitz et al., 1992; Lowe, 1995) . However, indirect evidence suggests that p53 also plays a role in the cell cycle. p53 is induced in response to growth signals (Reich and Levine, 1984) , hyperproliferative signals emanating from the overexpression of c-Myc, E2F-1, or E1A (Debbas and White, 1993; Hiebert et al., 1995; Zindy et al., 1998) , and its levels oscillate during the cell cycle (Bischo et al., 1990; Shaulsky et al., 1990 Shaulsky et al., , 1991 . Moreover, p53 can physically interact with E2F-1, as well as with its dimerization partner, DP-1 (O'Connor et al., 1995; Sorensen et al., 1996) . Immortal 32D.3 myeloid cells contain wild-type p53 but do not express p19 ARF . Regulated expression of E2F-1 in 32D.3 cells induces p53, but not apoptosis, when these cells are cultured in the presence of the survival factors IL-3 and serum (Hiebert et al., 1995) . Moreover, E2F-1-induced apoptosis in these cells is p53-independent (Hiebert et al., 1995; Nip et al., 1997) , allowing us to dissect the p53 response to E2F-1. Mapping studies demonstrated that the E2F-1 amino terminus contains two p53 interaction domains. Functional studies indicated that the E2F-1-mediated induction of p53 was due to stabilization of p53 protein, and that this stabilization was independent of cell cycle phase, transit through the cycle, and cell viability. Surprisingly, p53 was also induced in cells overexpressing a transactivation defective E2F-1 protein that is incapable of promoting either cell cycle progression or apoptosis. Thus, p53 responds to changes in the steady state levels of E2F-1, rather than its ability to stimulate transcription or induce cell cycle progression. Finally, expression of E2F-1 impaired p53-mediated transactivation functions. Collectively, the data suggest a model whereby p53 is stabilized by E2F-1 through associations that serve to keep E2F-1 activity in check, yet these associations also impair the ability of p53 to activate transcription.
Results

Two domains of E2F-1 interact with p53
Overexpression assays demonstrated that E2F-1 binds p53 (O'Connor et al., 1995) . To determine if E2F-1 could physically interact with endogenous p53 in 32D.3 myeloid cell lines, we used a panel of E2F-1 deletion mutants that lack various functional domains of E2F-1 (Figure 1a ). To characterize these E2F mutants with respect to their ability to transactivate E2F target genes, transcriptional reporter assays were performed using the human p14 ARF promoter (coupled to a luciferase reporter). Human p14 and its murine homologue p19, are induced, both at the mRNA and protein levels, by enforced expression of E2F-1 (Bates et al., 1998; DeGregori et al., 1997; Robertson and Jones, 1998) and E2F-2 (DeGregori et al., 1997) . E2F-1 and E2F-1D24 activated the p14 promoter/luciferase reporter in excess of 80-fold above basal levels ( Figure  1b) . By contrast, E2F-1 mutants which lacked the transactivation or DNA binding domains (E2F-1D374, E2F-1D195, E2F-1D119) failed to activate the p14 promoter (Figure 1b) .
To address the in vivo physical interaction of these E2F-1 mutants with p53, we used clonal 32D.3 cell ARF -promoter-luciferase plasmid by E2F-1 and E2F-1 mutants. MCF-7 cells were transfected with 10 ng of pCMV5 containing wild-type E2F-1 or E2F-1 mutants, 1 mg of pCMV5-p14 ARF -promoter-luciferase plasmid, and 200 ng of a pCMV5-SEAP (internal control for transfection eciency) and processed for luciferase activity 48 h post-transfection as described in Materials and methods. Adjusted luciferase activity values re¯ect a correction for transfection eciency as determined by SEAP activity. Wild-type E2F-1 or E2F-1 mutants tested are indicated on the abscissa. The basal activity of the p14 ARF promoter was measured in the absence of E2F-1. Shown are the means and average deviation of duplicate samples lines expressing the E2F-1 deletion mutants for coimmunoprecipitation studies. E2F-1 or E2F-1 mutant proteins were expressed from the pMAM-neo vector at low basal levels and the expression was further augmented by the addition of dexamethasone to the culture media. Cell extracts were immunoprecipitated with an anti-p53 antibody and associated E2F-1 was measured by immunoblot analysis. E2F-1 coimmunoprecipitated with p53, but was not immunoprecipitated by normal sheep serum (Figure 2a control  lane) , or an irrelevant monoclonal antibody directed to murine actin (data not shown). Likewise, E2F-1D374 protein coimmunoprecipitated with p53 and additional E2F-1D374 was coimmunoprecipitated with p53 following induction with dexamethasone ( Figure 2a ). In fact, while the panel of mutations aected each of the known E2F-1 functional domains, each mutant retained the ability to associate with p53 (Figure 2b ), suggesting that E2F-1 contains more than one p53 binding domain.
To de®ne the regions of E2F-1 responsible for p53 interaction, in vitro association assays using GST-E2F-1 fusion proteins were performed. E2F-1 deletion mutants were expressed as GST fusion proteins ( Figure  3a ) and tested for their ability to interact with in vitro 35 S-labelled p53. Although the full-length GST-E2F-1 fusion protein was produced poorly in our hands, a GST-fusion protein (1 ± 190) containing the ®rst 190 amino acids of E2F-1 interacted with p53 and GST-E2F-1(190 ± 437) more weakly associated with p53 ( Figure 3b , left panel). The E2F-1 fusion protein containing amino acids 120 ± 320, which encompasses the DP-1 interaction domain, failed to bind p53, implying that the weak association with GST-E2F-1(190 ± 437) was not mediated by DP-1 (Figure 3b ). Further deletions of E2F-1 revealed that the ®rst 119 amino acids were sucient to allow p53 interaction ( Figure 3b , center and right panels) and that the removal of most of the E2F-1 cyclin A/cdk2 binding domain (1 ± 119D24) abolished p53 association with E2F-1 (Figure 3b , right panel). Thus, the predominant domain for p53 association is in or around the cyclin A-binding domain of E2F-1, although a weaker interaction domain maps to the C-terminal domain (Figure 3b and O'Connor et al., 1995; Sorensen et al., 1996) . A similar approach was used to pinpoint the domain of p53 required for binding to E2F-1 (Figure 4a) . A series of GST-p53 fusion proteins were used to purify in vitro synthesized 35 S-labeled E2F-1. Full-length p53 (1 ± 393) and p53 (1 ± 160) associated with E2F-1 whereas other portions of p53 failed to bind to E2F-1 (Figure 4b) . However, the best interaction was consistently observed with amino acids 45 ± 145 of p53 (C-terminal to the domain required for p53 binding to Mdm2). Given that two domains of E2F-1 contacted p53, this region may contain two E2F-1 binding domains, or the second domain may be too weak to detect under these conditions. Both E2F-1 and p53 associate with Mdm2 (Martin et al., 1995; Momand et al., 1992) . Because the E2F-1 binding motif mapped just C-terminal to the Mdm2 binding domain on p53, we asked whether the association between E2F-1 and p53 was stabilized by forming a trimeric complex with Mdm2. In 32D.3 cells, a p53 and Mdm2 complex was detected, but only when E2F-1 induced higher levels of p53 ( Figure 5 , right, middle and bottom panels, lane 2). Although p53 and Mdm2 did interact, we did not observe a trimeric E2F-1:Mdm2:p53 complex; E2F-1 was never detected in Mdm2 immune complexes or vice versa ( Figure 5 ). Thus, it appears that Mdm2 and E2F-1 bind p53 independently.
E2F-1+DP-1 induces p19
ARF -independent, post-translational stabilization of p53
The viral E1A oncoprotein induces post-translational stabilization of p53 and E2F-1 also causes an accumulation of p53 (Hiebert et al., 1995; Kowalik et al., 1995 Kowalik et al., , 1998 . To probe the consequences of the E2F-1/p53 association for p53 function, we initially determined whether E2F-1 caused a post-translational stabilization of p53. Pulse-chase analysis indicated that the p53 protein that accumulated in response to the induction of E2F-1 plus DP-1 had a signi®cantly longer half-life (*90 min) than p53 in control 32D.3 cells containing the empty pMAMNeo vector (*45 min) ( Figure 6a ). Four hours after chase, p53 protein was still detectable in the E2F-1/DP-1 cells, whereas the radiolabeled p53 was undetectable in the control cells. Enforced inducible expression of high levels of DP-1 alone in these cells did not lead to p53 stabilization (data not shown). Thus, p53 is posttranslationally stabilized approximately twofold in response to E2F-1/DP-1.
One possible mechanism of p53 stabilization by E2F-1 could be through the E2F-1-mediated activation of the p19 ARF gene (Bates et al., 1998; DeGregori et al., 1997; Robertson and Jones, 1998) . p19 ARF can bind to Mdm2 and prevent it from targeting p53 for ubiquitinmediated degradation, thus causing p53 stabilization (Pomerantz et al., 1998; Zhang et al., 1998) . p19 ARF stabilizes p53 by sequestering Mdm2 in the nucleolus (Weber et al., 1999) and inhibiting the shuttling of p53 by Mdm2 from the nucleus to the cytoplasm (Tao and , an event believed to be required for p53 degradation. However, parental 32D.3 cells or 32D.3 cells expressing E2F-1+DP-1 or the DNA-binding defective E2F-1, E2F-138, failed to express p19 ARF protein following induction of E2F-1 and DP-1 with dexamethasone ( Figure 6b , upper panel). The lack of p19 ARF was con®rmed by RNA blot analysis and by reverse-transcriptase polymerasechain reaction assays (data not shown). The levels of the pro-apoptotic protein Bax, were also not aected by the induction of E2F-1 (Figure 6b , middle panel). As expected, p53 levels were elevated in E2F-1+DP-1 clones treated with dexamethasone ( Figure 6b , lower panel), but were not elevated in E2F-138-expressing cells (Figure 6b, lower panel) . As controls for S-methionine labeled in vitro translated E2F-1. Native GST proteins were used as a negative control for E2F-1 binding (lane labeled GST Control). The`Input E2F-1' lane represents 10% of the total labeled E2F-1 used per GST puri®cation assay. Equal amounts of GST fusion proteins were used for each sample. Shown are representative results of triplicate experiments Figure 5 Interactions between E2F-1, p53, and Mdm2. Coimmunoprecipitation experiments were performed using total cellular protein from lysates of 32D.3 (lane 1) or E2F-1.1/DP-1.2-expressing cell lines (lane 2), cultured with 25 mM dexamethasone. Lysates were immunoprecipitated with either Ab-7 (p53), KH-20 (E2F-1), or 2A10 (Mdm2) and sequentially immunoblotted with antibodies against the other two proteins to identify coprecipitating proteins. Shown is a representative experiment of three independent experiments. Ig H represents the immunoglobulin heavy chain immunoblotting, MEFs de®cient in p53 or harboring mutant p53 expressed high levels of p19 ARF , whereas MEFs from p19 ARF 7/7 mice did not (Figure 6b , upper panel). Thus, p53 stabilization by E2F-1 can also occur in the absence of the p19 ARF protein.
E2F-1-mediated induction of p53 is independent of cell cycle progression
To determine if E2F-1-induced accumulation of p53 is due to a direct response to E2F-1 levels, or is mediated by events associated with inappropriate cell cycle progression, 32D.3 cells expressing E2F-1/DP-1 were treated with the immunosuppressant rapamycin to arrest cells in the G 1 phase. Cell cycle arrest was con®rmed by propidium iodide staining and¯ow cytometric analysis for DNA content (Figure 7a ). Following cell cycle arrest, the cells were treated with dexamethasone to induce E2F-1 and DP-1 levels and aliquots of these cells were lysed and p53 levels were analysed by immunoblotting. Induction of E2F-1 plus DP-1 failed to override rapamycin-induced cell cycle arrest (data not shown). As expected, addition of dexamethasone to parental 32D.3 cells did not lead to any increases in the levels of p53 in the absence or presence of rapamycin ( Figure 7b , lanes 5 ± 8). By contrast, induction of E2F-1 levels with dexamethasone led to p53 accumulation whether or not these cells were arrested with 1 mM rapamycin ( Figure 7b , lanes 2 and 4). Therefore, induction of p53 appears to be a direct response to increases in E2F-1 levels, and is independent of transit through the G1 phase of the cell cycle.
Induction of p53 by E2F-1 is independent of E2F-1 transactivation functions E2F-1D374, a truncated form of E2F-1, lacks the transcriptional transactivation domain, including the pRb and CREB-binding protein (CBP) interaction domains . To assess whether E2F-1 transactivation functions were required for the induction of p53, the E2F-1D374-expressing cell lines were used. E2F-1D374 protein expressed in these cells bound to consensus E2F-1 DNA binding sites as measured by electrophoretic mobility shift assay (data not shown). In contrast to E2F-1- (Hiebert et al., 1995) or E2F-1/DP-1-expressing cells (Figure 8a , right panel), cells expressing E2F-1D374 arrested in G 1 when cultured in media lacking IL-3, con®rming that the E2F-1 transactivation functions are required for E2F-1 to promote continued cell cycle progression (Figure 8a , center panel). Immunoblot analysis of cell lysates showed an induction of E2F-1D374 protein upon dexamethasone addition (Figure 8b, upper panel) . Unexpectedly, p53 levels simultaneously accumulated (Figure 8b , lower panel). The ability of this transactivation-de®cient E2F-1 mutant to also induce p53 Figure 6 E2F-1 induces a p14 ARF -independent, post-translational stabilization of p53. (a) Cell lines overexpressing E2F-1 together with DP-1 were treated with dexamethasone (25 mM) for 6 h and subsequently used for pulse-chase analysis as described in Materials and methods. p53 protein was immunoprecipitated from radiolabeled lysates (2610 7 c.p.m./sample) using p53-speci®c antibody PAb421. Aliquots of the samples were analysed at the indicated times (hours) following chase. (b) 32D.3 cells and their E2F-1 derivatives do not express p19 ARF protein. E2F-1/DP-1-expressing or parental 32D.3 cells were treated with dexamethasone for 16 h to induce E2F-1/DP-1 protein expression. Cells were harvested and prepared for immunoblot analysis as previously described . Sequential blotting for Bax (antibody N-20) and p53 (antibody Ab-7) was also performed. Controls for p19 ARF expression were lysates derived from p53 underscores the concept that cell cycle progression is not required for p53 induction by E2F-1, and suggests that p53 responds directly to changes in steady state levels of E2F-1.
The hypoxia-inducible factor 1a protein and p53 physically interact and this interaction may contribute to stabilization of p53 protein . To determine whether the interaction of E2F-1 with p53 contributes to p53 stabilization, we induced the expression of E2F-1 or the E2F-1 mutant proteins in 32D.3 cells by the addition of dexamethasone and assessed their ability to induce p53. Deletion of the major interaction domain on E2F-1, the cyclin A binding domain, amino acids 79 ± 103, impaired the ability of E2F-1 to stabilize p53 (Figure 8c , upper left panel, bottom row), suggesting that physical interaction contributes to p53 stabilization. However, two DNA binding-de®cient mutants of E2F-1, E2F-138 and E2F-1D119 that interact with p53, failed to stabilize p53, indicating that an intact E2F-1 DNA binding domain was required (Figure 8c , bottom rows, upper and lower right panels). The lack of function of a fulllength E2F-1 with a linker insertion in the DNA binding domain, suggests a mechanism other than (or in addition to) blocking MDM2 binding to p53. Similarly, the E2F-1 mutant (E2F-1D195) that lacks the C-terminal DP-1 heterodimerization and transactivation domains, also failed to induce p53. Therefore, p53 stabilization by E2F-1 requires the DNA binding domain, the D24 domain, and sequences between E2F-1 residues 195 and 374 (Figure 8c , lower left panel, bottom row) for p53 stabilization.
E2F-1 impairs p53-dependent transactivation
The association of p53 with E2F-1 blocks the ability of E2F-1 to bind DNA and to transactivate gene expression (Sorensen et al., 1996) . However, the physiological eects of E2F-1/p53 complex formation on p53 transcriptional activity have not been tested. In some cell types, the apoptosis-stimulating gene Bax is regulated by p53 (Miyashita and Reed, 1995) ; however, we did not detect any alterations in Bax protein levels in E2F-1 expressing cells (Figure 6b ). Therefore, we also assessed the levels of the p21 Cip1/Waf1 CDK inhibitor in response to E2F-1-mediated p53 accumulation. Like Bax, the levels of p21 were unchanged following the induction of E2F-1 (Figure 9a ). However, a temperature-sensitive mutant of p53 was able to induce p21 expression in 32D cells at the permissive temperature. Because DNA damage causing only a moderate induction of p53 did lead to elevation of p21 levels (Hiebert et al., 1995) , we conclude that E2F-1-mediated induction of p53 failed to induce p53 target gene expression.
The lack of p21 or Bax induction in response to E2F-1 suggested that E2F-1 might impair the ability of p53 to activate transcription. Therefore, we tested the eects of E2F-1 and E2F-1 mutants on p53-mediated transactivation in transient expression assays with an idealized p53-reporter plasmid. Using p53-null 10-1 cells, when expressed separately, p53 activated this promoter and E2F-1 and its deletion mutants had little or no eect (Figure 9b) . However, when co-expressed, E2F-1 displayed a dose-dependent impairment of p53- Figure 8 Induction of p53 by E2F-1 is independent of E2F-1 transactivation functions. (a) E2F-1D374 overexpressing cells arrest in the G 1 phase of the cell cycle in the absence of IL-3. Cells were divided to a density of 0.5610 6 cells/mL and cultured in the absence of IL-3 for 16 h prior to¯ow cytometric analysis. Apoptotic cells in the E2F-1.1/DP-1.2 sample were gated out. Shown are the results of duplicate experiments using a representative clone. (b) E2F-1 transactivation domain is not required for induction of p53. Representative clones of E2F-1D374 were cultured in the absence (7) or presence (+) of 25 mM dexamethasone and whole cell lysates of these cells were immunoblotted for E2F-1 (antibody KH20, upper panel), and p53 (Ab-7, lower panel). (c) E2F-1 DNA binding is required for p53 stabilization. Representative clones of E2F-1D24, E2F-138, E2F-1D195, and E2F-1D119 were cultured in the absence (7) or presence (+) of 25 mM dexamethasone and total cellular protein extracts from these cells were processed for SDS ± PAGE and immunoblotting. Detection of E2F-1 proteins was carried out using KH-20 antibodies for all E2F-1 proteins except E2F-1D24, which was detected by a rabbit polyclonal antibody directed against the pRb-binding domain of E2F-1. Blots were reprobed with Ab-7 for the detection of p53 dependent transactivation (up to ®vefold, Figure 9b ). The ability of E2F-1 to inhibit p53-dependent transactivation required the E2F-1 transactivation domain as the D195 and D374 mutants had no eect, or actually cooperated with p53 to activate transcription (Figure 9b , note that at lower levels of E2FD374 it also cooperated with p53, data not shown). By contrast, E2F-1D24, which lacks one of the p53 binding sites and was impaired in p53 stabilization, had only small eects on p53 function. Further, the DNA binding de®cient E2F-1D119, that failed to induce p53, did not signi®cantly aect p53 function, suggesting that the inhibition of p53 function was not due to E2F-1 binding to p300. These results are summarized in Figure 9c . Thus, E2F-1 may bypass the p53 checkpoint, at least in part, through canceling p53-mediated transactivation functions.
Discussion
Mapping studies indicated that E2F-1 contains two p53-binding domains (Figures 2 and 3 ; O'Connor et al., 1995; Sorensen et al., 1996) . The functional outcome of inducing the E2F-1/p53 association in immortalized myeloid cells was p53 post-transcriptional stabilization that was independent of p19 ARF . E2F-1-dependent induction of p53 was also independent of cell cycle progression. p53 accumulation was even observed with forms of E2F-1 that lack transcriptional activity and are defective in promoting cell cycle progression. These data imply that p53 responds directly to changes in steady state levels of E2F-1, rather than through E2F-1-mediated events caused by the induction of inappropriate cell cycle progression. Furthermore, E2F-1-mediated stabilization of p53 requires domains of E2F-1 that physically contact p53 in addition to the E2F-1 DNA binding domain. The outcome of the physical association of E2F-1 and p53 is that p53-dependent transactivation is impaired, suggesting that this allows E2F-1 to bypass the p53 checkpoint and promote S phase entry.
E2F-1-transactivation defective mutants, such as D374, can physically interact with p53 and cause accumulation of p53 (Figure 8 ), yet unlike E2F-1, these mutants fail to induce cell cycle progression or impair p53-mediated transactivation functions ( Figure  9 ). We have also tested the eect of wild-type and mutant E2F-1 on p53-dependent transrepression of the MAP4 and topoisomerase IIa promoters (Murphy et al., 1996 (Murphy et al., , 1999 Wang et al., 1997) . However, in both cases E2F-1 alone activated these promoters. Thus, while p53 still moderately repressed in the presence of E2F-1 in these assays, we could not assess whether E2F-1 aected p53-mediated repression or simply activated these promoters (data not shown). However, we did note that in 32D.3 cells expressing wild-type E2F-1, but not the D374 mutant, that levels of the endogenous topoisomerase IIa were signi®cantly reduced (data not shown). Thus, it appears that E2F-1 may suppress p53-dependent transactivation (Figure 9 ), but not p53-dependent transrepression. Given that p53-dependent repression has been associated with p53-induced cell death (Sabbatini et al., 1995) , this result could explain how E2F-1 and p53 can cooperate to induce apoptosis in some cell types (Wu and Levine, 1994) . Alternatively, E2F-1 may directly or indirectly modulate topoisomerase IIa levels, independent of p53.
Transactivation-defective forms of E2F-1 have diering activities when overexpressed in divergent cell types including the induction of apoptosis or the stimulation of cell cycle progression (Hsieh et al., Phillips et al., 1997; Zhang et al., 1999) . In immortalized 32D.3 myeloid cells, only wild-type E2F-1 induced apoptosis when cultured in the absence of IL-3 (Nip et al., in preparation) and E2F-1 mutants that lacked transactivation functions failed to induce cell cycle progression. In addition, while wild-type E2F-1 blocked p53-mediated transactivation, mutants that bound and stabilized p53, but lacked the activation domain, cooperated with p53 to activate transcription ( Figure 9 ). The ability of E2F-1 to bind p53 and modulate its activity may explain some of the diverse phenotypes ascribed to E2F-1 and its derivatives.
In MEFs, the cell cycle checkpoint function of p53 is associated with the co-stimulation of the p19 ARF tumor suppressor, yet as demonstrated here, E2F-1 induction of p53 can be p19 ARF -independent, as 32D.3 cells lack detectable levels of the p19 ARF protein or mRNA ( Figure 6 and data not shown). The overall cellular response to E2F-1 overexpression, therefore, appears to be an attempt to inactivate E2F-1 by p53. This model is supported by the observations that p53 can also interact with DP-1, and studies demonstrating that p53 blocks E2F-1-dependent transactivation (O' Connor et al., 1995; Sorensen et al., 1996) . In addition, the major in vitro p53-interaction domain of E2F-1 encompasses the cyclin A/cdk2 binding region and removal of this motif disrupts the proper regulation of E2F-1 transcription functions . Thus, it is possible that p53 also competes for cyclin A binding to disrupt E2F-1-dependent transcriptional control.
A physical interaction between p53 and hypoxiainducible factor 1a protein has been hypothesized to contribute to p53 stabilization . Two domains of E2F-1 were identi®ed that contact p53, and DP-1 also interacts with p53 (O'Connor et al., 1995; Sorensen et al., 1996) . Given that the domains that were required for p53 stabilization include a p53 interaction domain, the E2F-1 DNA binding domain and the DP-1 interaction motif, it is possible that for E2F-1 to stabilize p53 it must contact p53 and DP-1 (and perhaps DNA) at the same time. Nevertheless, our studies indicate that p53 responds to the levels of E2F-1, not to its transcriptional activation functions.
DNA tumor viruses target both p53 and pRb for inactivation, leading to the induction of cell cycle progression. The targeting of p53 was thought to be due to the ability of p53 to induce apoptosis. However, in our cell system E2F-1-induced apoptosis is independent of p53 (Hiebert et al., 1995; Nip et al., 1997) , allowing us to assess its additional roles in regulating E2F-1-dependent cell cycle control. The adenovirus E1B gene encodes two proteins that have been postulated to aect apoptosis, 55K and 19K. The E1B 19K protein is homologous to Bcl-2 and inhibits cell death (Han et al., 1996) , whereas the 55K protein binds to the N-terminal p53 transactivation domain and inhibits the ability of p53 to activate transcription. Thus, it is possible that adenovirus has evolved the E1B 55K protein not only to block p53-mediated apoptosis (Lin et al., 1994) , which can also be suppressed by 19K (Han et al., 1996; Sabbatini et al., 1995) , but also to prevent p53 from binding E2F-1 to inhibit cell cycle progression.
Materials and methods
Cell lines and cell cycle analysis
The culture of parental 32D.3 myeloid progenitor cells and establishment of E2F-1 mutant-expressing cell lines was performed as previously described (Hiebert et al., 1995; Nip et al., 1997) . The 32D.3 cell lines overexpressing E2F-1, DP-1, and E2F-138 have been described (Hiebert et al., 1995; Nip et al., 1997) . Mouse embryo ®broblasts (MEF) (p53 null, p19 ARF null, or mutant p53) were isolated and characterized as previously described . 32D.3 cells overexpressing the E2F-1D374 truncation mutant (encompassing aa 1 ± 374 of E2F-1) (Helin et al., 1993) and the E2F-1D24 mutant (deleting aa 79 ± 103) , were generated as described earlier (Hiebert et al., 1995; Nip et al., 1997) . To generate the E2F-1D195 construct, an XbaI/ MslI fragment encoding the ®rst 195 amino acids of E2F-1, containing an added in-frame stop codon along with¯anking XbaI-linkers, was subcloned into an engineered XbaI site in pMAM-Neo. A PCR strategy was used to construct E2F-1D119 ± 181, an E2F-1 DNA binding domain deletion mutant, through the ligation of two separately synthesized PCR fragments corresponding to aa 1 ± 118 and aa 182 ± 437 of E2F-1 and subcloned into pMAM-Neo. The primer pairs used to amplify the fragments were as follows: E2F 1 ± 118 (5'-ATTCTAGAGCTAGCATGGCCTTGGCCGGG-3'; 5'-ATGGATCCTTTCACACCTTTTCCTGGATG-3'); E2F 182 ± 437 (5'-ATGGATCCTCCAAGAACCACATCCAG-3'; 5'-ATTCTAGATCAGAAATCCAGGGGGGT-3'). Sequencing (both strands) con®rmed the accuracy of the PCR product. Cell lines transfected with the pMAM-Neo vector constructs were treated with 25 mM dexamethasone to induce E2F-1 protein expression. Single cell cloning of transfectant pools was performed by limiting dilution.
Cell cycle analysis was performed by¯ow cytometry as described previously (Krishnan, 1975; Nip et al., 1997) . Tenthousand total events were analysed per sample. The ModFit computer program (Verity Software House, Topsham, ME, USA) was used to generate the histograms and to determine the percentage of cells within the G1 phase of the cell cycle.
Antibodies and drugs
Immunoblots were performed as described previously (Nip et al., 1997) , using the following antibodies: a rabbit polyclonal anity-puri®ed antibody directed against the pRb-binding domain of E2F-1 (Hiebert et al., 1995) ; a mouse monoclonal antibody directed to the N-terminal region (aa 1 ± 89) of E2F-1 (KH-20) (Helin et al., 1993) ; a sheep polyclonal antiserum directed to murine p53 (Ab-7, Oncogene Science, Cambridge, MA, USA); a mouse monoclonal antibody directed to human p53 and reacting with murine p53 (PAb 421); a mouse monoclonal antibody (2A10) made against human Mdm2 protein (aa 294 ± 339) and cross-reacting with murine Mdm2 (Olson et al., 1993) ; a rabbit antibody directed to the carboxy terminus of murine p19 ARF (Quelle et al., 1995) , a rabbit polyclonal antibody (N-20) made to the N-terminus of human Bax (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA), anti-p21 Ab-5 (CalBiochem) and normal sheep serum (Oncogene Science, Cambridge, MA, USA). Immune complexes were detected using the SuperSignal 1 Chemiluminescent detection system (Pierce, Rockford, IL, USA).
The dexamethasone (Sigma, St. Louis, MO, USA), and rapamycin (Calbiochem, San Diego, CA, USA) were added to the cell culture medium as indicated in the results and ®gure legends.
Cell cycle arrest and p53 induction experiments E2F-1/DP-1 overexpressing cells were treated with the indicated drugs for 16 ± 30 h, at 378C and an aliquot analysed by¯ow cytometry to con®rm cell cycle arrest. The doses of the drugs used in this study were chosen to give maximal cell cycle arrest and minimal cytotoxicity. Following cell cycle arrest, E2F-1 was induced by addition of dexamethasone (25 mM) for 8 h. Cells ( 1610 7 ) were collected, washed in PBS, and processed for Western blot analysis of p53 protein as described below.
For half-life determinations, cells (0.3610 6 /mL) in replete medium were treated with dexamethasone (25 mM) for 6 h. They were then cultured in methionine-and cysteine-free complete RPMI medium for 30 min and metabolically labeled with 1 mCi 35 S-Translabel (ICN; Irvine, CA, USA) for 2 h. Cells were washed extensively and cultured in complete media containing excess unlabeled methionine and cysteine (chase). At the indicated intervals, cells were harvested for immunoprecipitation analysis. Radiolabeled cellular proteins were quantitated by trichloroacetic acid (TCA) precipitation (Olson and Levine, 1994) and normalized prior to analysis (2610 7 c.p.m./sample). Following electrophoresis, the gels were treated with sodium salicylate and glycerol to amplify the 35 S signals. The gels were dried under vacuum at 808C and exposed to X-ray ®lm (Kodak XAR5). The samples were quantitated using a BioImage Visage 110 Kodak camera and BioImage whole band analyser software (version 3.3).
Coimmunoprecipitation experiments and electrophoretic mobility shift assays (EMSA) Cells were lysed in TENN buer (50 mM Tris-Cl pH 7.4, 5 mM EDTA, 150 mM NaCl and 0.5% NP-40) containing proteinase inhibitors, sonicated, and clari®ed by centrifugation at 10 000 g for 5 min. Two mg of total cellular protein was incubated with the appropriate primary antibody overnight at 48C. Subsequently, immune complexes were isolated by the addition of Protein G Sepharose 4B (Sigma, St. Louis, MO, USA). The beads were washed three times in TENN buer, resuspended in SDS sample buer and analysed by immunoblot analysis (Nip et al., 1997) .
Luciferase reporter assay
The cDNA for all the E2F-1 mutants described above were subcloned into the pCMV5 plasmid. Ten ng of pCMV5 constructs containing E2F-1 or E2F-1 mutants were transfected along with 1 mg of a vector containing the human p14 ARF promoter (Robertson and Jones, 1998) coupled to a luciferase reporter gene into MCF-7 breast carcinoma cells, using the SuperFect transfection reagent (Qiagen, Inc., Santa Clarita, CA, USA). The transfection was performed according to the manufacturer's protocol. Forty-eight hours posttransfection, cells were lysed and processed for luciferase activity using the Luciferase assay reagent (Promega, Madison, WI, USA) according to manufacturer's instructions. Light intensity was measured using a Monolight 2010 Luminometer (Analytical Luminescence Laboratory, San Diego, CA, USA). Transfection eciency was determined by quantitation of secreted alkaline phosphatase (SEAP) activity following co-transfection of a pCMV5-SEAP reporter construct as previously described (Berger et al., 1988) . The adjusted luciferase activity values were normalized with respect to SEAP activity.
Glutathione S-transferase (GST) fusion protein expression, purification, and in vitro glutathione-sepharose pull-down experiments GST-E2F fusion proteins were generated by subcloning PCRampli®ed, E2F-1 deletion and truncation mutants, into the prokaryotic GST gene fusion expression vector, pGEX-4T-1 (Pharmacia Biotech, Piscataway, NJ, USA). The E2F-1 mutant PCR-generated DNA fragments contained engineered EcoRI/ XhoI or EcoRI/SalI restriction site pairs. The fragments were subcloned into pGEX-4T-1 digested with EcoRI/XhoI. The following oligonucleotide primer pairs were used to generate the E2F-1 mutants: 1 ± 190 (5'-TCCCCGGAATTCATGGCC-TTGGCCGGG-3', 5'-CGGCCGCTCGAGCCACTGGATG-TGGTTCTT-3'; 120 ± 320 (5'-TCCCCGGAATTCAAATCC-CCGGGGGAGAAG-3', 5'-CGGCCGCTCGAGCTCCTCA-GAAGTGACCTC-3'); 190 ± 43 (5'-TCCCCGGAATTCTGG-CTGGGCAGCCACACC-3', 5'-CGGCCGGTCGACATCA-GAAATCCAGGGGGGT-3'); 1 ± 64 (5'-TCCCCGGAATT-CATGGCCTTGGCCGGG-3', 5'-CGGCCGCTCGAGCAG-CAGGTCAGGGTCGCA-3'); 1 ± 119 and 1 ± 119D24 (5'-TCCCCGGAATTCATGGCCTTGGCCGGG-3', 5'-CGGC-CGCTCGAGCACACCTTTTCCTGGATG-3'). The PCR DNA template was the pMAM-Neo vector containing fulllength E2F-1 for all the mutants except 1 ± 119D24, where the template was pMAM-Neo-E2F-1D24. GST-p53 fusion proteins were constructed as previously described .
The GST fusion proteins were expressed and puri®ed as previously described (Hiebert, 1993) . The puri®ed fusion proteins were isolated by incubation with glutathione sepharose 4B beads for 30 min at 48C. The beads were washed three times with PBS and resuspended in TENN buer. Bound GST fusion protein was analysed by electrophoresis through a 10% SDS-polyacrylamide gel followed by Coomassie Blue R-250 staining and methanol/ acetic acid destaining.
E2F-1 or p53 was synthesized in vitro using the TNT reticulocyte lysate-coupled transcription/translation system with and without 35 S-methionine (Promega, Madison, WI, USA). For the glutathione-sepharose pull-down experiments, 35 S-labeled p53 or E2F-1 (10 mL of a 50 mL reaction) and equal amounts of glutathione sepharose-bound GST fusion proteins were mixed together in 200 mL TENN buer containing protease inhibitors and incubated for 1.5 h at 48C. The sepharose beads were washed three times in TENN lysis buer, resuspended in SDS sample buer, heated to 1008C, vortexed, and analysed on a 10% SDS-polyacrylamide gel. Following electrophoresis, the gel was destained and subjected to¯uorography. The gel was dried and exposed to X-ray ®lm (Kodak X-OMAT AR) at 7808C.
